Setback for diabetes innovation: FDA puts brakes on Novo Nordisk’s once-weekly insulin icodec

Novo Nordisk announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application for its ... Read More